DocGo (DCGO) Aktienübersicht
DocGo Inc. ist ein Unternehmen für mobile Gesundheitsdienste in den Vereinigten Staaten und im Vereinigten Königreich. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
DCGO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DocGo Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$0.67 |
| 52-Wochen-Hoch | US$2.45 |
| 52-Wochen-Tief | US$0.49 |
| Beta | 0.98 |
| 1 Monat Veränderung | 18.32% |
| 3 Monate Veränderung | -13.22% |
| 1 Jahr Veränderung | -70.81% |
| 3 Jahre Veränderung | -91.98% |
| 5 Jahre Veränderung | -93.22% |
| Veränderung seit IPO | -93.45% |
Aktuelle Nachrichten und Updates
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.
DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.Recent updates
DCGO: Transport EBITDA Outlook Will Drive Future Upside Potential
Analysts recently trimmed their DocGo price targets, with cuts such as Stifel's move from $4.00 to $2.50, citing mixed Q4 results, modestly higher 2026 transport guidance, and updated expectations for growth, margins, and P/E assumptions. Analyst Commentary Bullish analysts acknowledge the recent price target cuts but still point to several areas they see as supportive for DocGo's valuation and long term execution story.DCGO: Transport EBITDA And 2026 Guidance Will Drive Future Upside Potential
Narrative Update Analysts have nudged their price expectations for DocGo lower, trimming aggregate targets by around $0.10 as they factor in mixed Q4 results, modestly higher 2026 transport guidance, and updated views on margins, growth, and future P/E multiples. Analyst Commentary Recent Street commentary on DocGo is mixed, with some analysts focusing on potential value in the transport segment and others reacting to lower price targets and Q4 variability.DCGO: Transport EBITDA Outlook Will Support Future Upside Potential
Narrative Update The analyst price target for DocGo has been reduced from $4.00 to $2.50, as analysts factor in mixed Q4 results while crediting modestly higher 2026 transport guidance and the view that the transport unit alone could potentially support proceeds above the current share price. Analyst Commentary Recent research reflects a more cautious stance on DocGo, with the price target reduced to US$2.50 while still crediting specific strengths in the transport segment.
DCGO: Future Returns Will Rely On Expanding Telehealth Weight Loss Services
Analysts have trimmed their price targets on DocGo to reflect slightly softer revenue growth assumptions, along with somewhat stronger profit margin and future P/E expectations, resulting in only a modest adjustment to their overall valuation view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the $1.00 minimum bid price requirement.DCGO: Buyback Extension And Telehealth Expansion Will Support Future Upside
Analysts have trimmed their price targets on DocGo to $2.50, citing slightly higher discount rate assumptions, a modestly softer profit margin outlook, and a higher future P/E multiple as key drivers of the revised view. What's in the News Nasdaq notified DocGo on January 26, 2026 that the company is not in compliance with the minimum US$1.00 bid price requirement, triggering a 180 day window until July 27, 2026 to regain compliance before potential further action is considered (Delistings).DCGO: Future Returns Will Rely On Expanding Longitudinal Virtual Weight Loss Care
Analysts have slightly reduced their price target on DocGo, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. This adjustment signals a more cautious stance on the company’s risk and earnings profile.DCGO: Buyback Extension And M&A Pipeline Will Support Future Upside
Analysts have trimmed their price target on DocGo to reflect a fair value shift from about $3.08 to roughly $2.50. The change reflects updated assumptions around revenue contraction, slightly higher required returns, modestly better profit margins, and a lower future P/E multiple.DCGO: Future Returns Will Depend On Expanding Longitudinal Care Partnerships
Analysts have made a small upward tweak to their price target on DocGo, reflecting slightly more constructive assumptions around revenue growth and long term profit margins, while keeping the projected P/E and discount rate almost unchanged. What's in the News Robbins Geller Rudman & Dowd LLP announced a proposed US$12.5 million cash settlement in the DocGo securities class action, subject to court approval at a hearing scheduled for March 24, 2026 in the Southern District of New York (Lawsuits & Legal Issues).DCGO: Future Returns Will Depend On Longitudinal Care And Maturing Revenue Mix
Analysts have nudged up their price target on DocGo by a modest amount, citing slightly higher long term profit margin expectations and a marginally richer future earnings multiple. Together, these factors support a small increase in estimated fair value.DCGO: Future Returns Will Depend On New Longitudinal Care Contracts
Analysts have lowered their price target on DocGo from approximately 1.60 dollars to 1.00 dollars, citing a higher required discount rate and a reduced valuation multiple, despite modest improvements in the projected revenue trajectory and profit margins. What's in the News DocGo signaled an active mergers and acquisitions strategy, highlighting its ability to acquire traditional health care assets and layer on its technology and mobile health capabilities to support long-term growth and shareholder value (company commentary) The company provided updated guidance, forecasting 2025 revenue of 315 million to 320 million dollars, including 68 million to 70 million dollars from migrant-related contracts, and 2026 revenue of 280 million to 300 million dollars with no migrant-related revenue (corporate guidance) DocGo recorded a goodwill impairment charge of approximately 8.7 million dollars in the third quarter of 2025, reflecting a write-down of acquired assets (company filing) DocGo announced a new Longitudinal Care Services program with a California-based insurer, targeting 10,000 under-engaged members with combined telehealth and in-home clinical services starting in the fourth quarter (client announcement) The company is expanding its partnership with a national insurer in New Mexico, launching care gap closure and planned primary care services for 10,000 Turquoise Care members through at-home visits and chronic care support (client announcement) Valuation Changes The fair value estimate has fallen significantly from approximately $1.60 to $1.00 per share.Benign Growth For DocGo Inc. (NASDAQ:DCGO) Underpins Its Share Price
Sep 26
DocGo Inc. (NASDAQ:DCGO) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
May 16Is It Too Late To Consider Buying DocGo Inc. (NASDAQ:DCGO)?
Apr 16We Like The Quality Of DocGo's (NASDAQ:DCGO) Earnings
Mar 06These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Mar 01Subdued Growth No Barrier To DocGo Inc. (NASDAQ:DCGO) With Shares Advancing 33%
Feb 11
Innovative Health Initiatives Promise Growth Amid Analysts' Concerns Over Future Earnings And Margins
Strategic partnerships with virtual-only providers and operational efficiency improvements indicate a comprehensive approach to expanding health solutions and improving margins.DocGo Inc. (NASDAQ:DCGO) Doing What It Can To Lift Shares
Aug 05At US$3.40, Is DocGo Inc. (NASDAQ:DCGO) Worth Looking At Closely?
Jul 17These 4 Measures Indicate That DocGo (NASDAQ:DCGO) Is Using Debt Safely
Jun 11DocGo: Upside Remains Attractive After Share Price Decline
Mar 20Does DocGo (NASDAQ:DCGO) Have A Healthy Balance Sheet?
Feb 13DocGo: Good Performance, Trust Issues
Feb 05Why DocGo Inc. (NASDAQ:DCGO) Could Be Worth Watching
Jan 25Fewer Investors Than Expected Jumping On DocGo Inc. (NASDAQ:DCGO)
Jan 04Aktionärsrenditen
| DCGO | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -6.1% | 3.5% | 0.8% |
| 1Y | -70.8% | -3.1% | 27.8% |
Rendite im Vergleich zur Industrie: DCGO unter dem Niveau der Branche US Healthcare , die im vergangenen Jahr eine Rendite von -3.1% erzielte.
Rendite vs. Markt: DCGO hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 27.8 erzielte.
Preisvolatilität
| DCGO volatility | |
|---|---|
| DCGO Average Weekly Movement | 13.0% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von DCGO war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: DCGODie wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2015 | 3,053 | Lee Bienstock | docgo.com |
DocGo Inc. ist ein Unternehmen für mobile Gesundheitsdienste in den Vereinigten Staaten und im Vereinigten Königreich. Das Unternehmen ist in den Segmenten Mobile Gesundheitsdienste und Transportdienste tätig. Das Unternehmen bietet Transportdienste an, die Notfalldienste und Nicht-Notfall-Transportdienste umfassen, wie z. B. Krankenwagen- und Rollstuhltransportdienste.
DocGo Inc.'s Grundlagenzusammenfassung
| DCGO grundlegende Statistiken | |
|---|---|
| Marktanteil | US$66.60m |
| Gewinn(TTM) | -US$182.40m |
| Umsatz(TTM) | US$322.20m |
0.2x
Kurs-Umsatz-Verhältnis-0.4x
Kurs-Gewinn-Verhältnis Ist DCGO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| DCGO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$322.20m |
| Kosten der Einnahmen | US$223.44m |
| Bruttogewinn | US$98.76m |
| Sonstige Ausgaben | US$281.16m |
| Gewinn | -US$182.40m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
May 11, 2026
| Gewinn per Aktie (EPS) | -1.85 |
| Bruttomarge | 30.65% |
| Nettogewinnspanne | -56.61% |
| Schulden/Eigenkapital-Verhältnis | 0.2% |
Wie hat sich DCGO auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/03 12:28 |
| Aktienkurs zum Tagesende | 2026/05/01 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
DocGo Inc. wird von 7 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Sarah James | Barclays |
| David Larsen | BTIG |
| Richard Close | Canaccord Genuity |